| Document |
Document Title |
|
WO/2024/082681A1 |
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furtherm...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/057094A3 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/083226A1 |
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to...
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
|
WO/2024/082795A1 |
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevent...
|
|
WO/2024/082262A1 |
Provided are a splicing system for controlling virus replication in response to a hypoxic environment, and a use thereof. The system comprises, mutually separated or fused to one another, a gene encoding an hypoxia sensing unit and a gen...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/082067A1 |
Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus ...
|
|
WO/2024/078485A1 |
The present invention belongs to the technical field of tumor immunotherapy, and specifically relates to a signal receptor used for targeting a tumor microenvironment and a cell for targeted treatment of tumors. The signal receptor compr...
|
|
WO/2024/077815A1 |
Provided are an adeno-associated virus capsid protein mutant having an unactivated T cell targeting property and the use thereof. The mutant comprises a sequence as shown in any one of SEQ ID Nos. 9-12. The recombinant adeno-associated v...
|
|
WO/2024/080304A1 |
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell su...
|
|
WO/2024/081876A1 |
Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineere...
|
|
WO/2024/081906A1 |
Technologies for the prevention and/or treatment of GBS infections. The technology relates to compositions, including vaccines compositions and methods comprising an immunogenic complex that is a GBS multiple antigen presenting system (M...
|
|
WO/2024/077776A1 |
Provided are a bifunctional molecule formed by connecting an Fc mutated antibody to a cytokine, and use of the bifunctional molecule in the preparation of a therapeutic antibody drug. These Fc mutated monoclonal antibodies or monoclonal ...
|
|
WO/2024/077775A1 |
Disclosed are a multifunctional recombinant antibody, a preparation method therefor, and use thereof. Provided is a monoclonal antibody able to specifically recognize human HER3 protein. Also provided is a humanized recombinant antibody ...
|
|
WO/2024/081929A1 |
Technologies for the prevention and/or treatment of pathogenic or microbial infections. Compositions relate to compositions, vaccines and methods comprising an immunogenic multiple antigen presenting system (MAPS), where two or more biot...
|
|
WO/2024/080305A1 |
According to one embodiment of the present invention, a bioactive protein that usually has a low expression level and/or low activity when expressed as a recombinant protein using a host cell such as a CHO cell can be expressed in the fo...
|
|
WO/2024/081381A1 |
Provides herein are multifunctional molecules comprising T cell receptor variable beta-binding moieties and cytokines, and methods of treating conditions or diseases in a subject using the same.
|
|
WO/2024/081879A1 |
This invention relates to compositions and methods comprising epigenetic editors for epigenetic modification of CD247, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigen...
|
|
WO/2024/081933A1 |
Described herein are methods and compositions for use in generating or promoting an immune response to cancer, comprising administering a combination of an immunotherapy using an immune checkpoint inhibitor, e.g., anti-PD-1 antibodies, a...
|
|
WO/2024/077672A1 |
Provided are cAMP green fluorescent probes G-Flamp2 and G-Flamp2b and the use thereof, and a kit. The cAMP fluorescent probe G-Flamp2 has an amino acid sequence as shown in SEQ ID NO: 1; and the other cAMP fluorescent probe G-Flamp2b has...
|
|
WO/2024/078368A1 |
A method for preparing a halogenated indole glucoside and Tyrian purple. The method comprises: a halogenation step, involving halogenating tryptophan to obtain halogenated tryptophan; and a glucoside preparation step, involving mixing th...
|
|
WO/2024/078479A1 |
The present invention relates to a heterodimeric fusion protein and the use thereof. The heterodimeric fusion protein of the present invention comprises: a first heavy chain, wherein the first heavy chain comprises a first Fc region and ...
|
|
WO/2024/081329A1 |
Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable beta-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same.
|
|
WO/2024/080306A1 |
According to one embodiment of the present invention, it is possible to efficiently produce a highly-active recombinant protein by expressing, in the form of a fusion protein with serum albumin (SA), a physiologically-active protein havi...
|
|
WO/2024/075851A1 |
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nu...
|
|
WO/2024/077170A1 |
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primat...
|
|
WO/2023/221936A9 |
Provided are a protein comprising a PD-L1 binding moiety linked to a TGF β binding moiety, an IL-1 binding moiety, an immunostimulating polypeptide (such as soluble LAG3 or soluble CD4) or a CD47 binding moiety, and a pharmaceutical pre...
|
|
WO/2024/067888A1 |
Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granulin component. The granulin component comprises a nanogranulin protei...
|
|
WO/2024/069180A2 |
Provided herein are multivalent protein scaffolds useful as therapeutics, and useful in identifying new therapeutic compounds. The invention also relates to multi-domain polypeptide constructs having multiple binding domains and a struct...
|
|
WO/2024/067756A1 |
The present invention relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/071397A1 |
The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-...
|
|
WO/2024/072897A1 |
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In pa...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/067401A1 |
The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, which comprises immunoglobulin Fc and an advanced fatty acid chain. The present invention also relates to prepara...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/067725A1 |
Provided are a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer of the recombinant F protein, and an immunogenic compo...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/066616A1 |
Provided is a high-affinity PD1 protein conjugate, which comprises an elastin-like polypeptide and a high-affinity PD1 protein connected to the elastin-like polypeptide. The conjugate significantly improves the biological half-life and b...
|
|
WO/2024/067785A1 |
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN whic...
|
|
WO/2024/072224A2 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/069240A2 |
Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in co...
|
